格隆汇1月23日丨健民集团(600976.SH)公布，公司于2026年1月23日召开第十一次董事会第六次会议， 会议全票审议通过《关于向中国健康促进基金会捐赠的议案》，公司拟以自有资金向中国健康促进基金 会捐赠人民币150万元，用于支持儿童呼吸与药学相关课题研究项目。 ...

格隆汇1月23日丨健民集团(600976.SH)公布，公司于2026年1月23日召开第十一次董事会第六次会议， 会议全票审议通过《关于向中国健康促进基金会捐赠的议案》，公司拟以自有资金向中国健康促进基金 会捐赠人民币150万元，用于支持儿童呼吸与药学相关课题研究项目。 ...

（记者 张明双） 每经头条（nbdtoutiao）——地方国资开始"抄底"法拍房！单价六七千元"扫货"广州南沙区超60套房 源，同小区二手房挂牌均价逾2万元 每经AI快讯，健民集团1月23日晚间发布公告称，公司第十一届第六次董事会会议于2026年1月23日以 通讯方式召开。会议审议了《关于向中国健康促进基金会捐赠的议案》等文件。 ...

证券代码：600976 证券简称：健民集团 公告编号：2026-002 捐赠金额：150 万元 中国健康促进基金会是中华人民共和国国务院批准、国家卫生健康委员会主管、 于 2006 年 12 月在国家民政部注册登记的公益慈善组织。2021 年，被民政部评为 4A 级全国性社会组织，2023 年，被国家卫生健康委直属机关党委评为先进基层党组织。 二、捐赠的基本情况 健民药业集团股份有限公司 关于对外捐赠的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 健民药业集团股份有限公司于 2026 年 1 月 23 日召开第十一次董事会第六次会 议，会议全票审议通过《关于向中国健康促进基金会捐赠的议案》，公司拟以自有资 金向中国健康促进基金会捐赠人民币 150 万元，用于支持儿童呼吸与药学相关课题 研究项目，具体如下： | 名称 | 中国健康促进基金会 | 法定代表人 | 韩萍 | | --- | --- | --- | --- | | 注册资金 | 壹仟柒佰万元整 | 社会组织类型 | 基金会 | | 设立时间 | 2006 ...

证券代码：600976 证券简称：健民集团 公告编号：2026-001 健民药业集团股份有限公司 1、关于向中国健康促进基金会捐赠的议案 同意：9 票 弃权：0 票 反对：0 票 公司拟以自有资金向中国健康促进基金会捐赠人民币 150 万元，用于支持儿童 呼吸与药学相关课题研究项目。详见中国证券报、证券时报、上海证券报及上海证 券交易所网站(http://www.sse.com.cn)《健民药业集团股份有限公司关于对外捐赠 的公告》。 二○二六年一月二十四日 特此公告。 健民药业集团股份有限公司 第十一届董事会第六次会议决议公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 董事会 健民药业集团股份有限公司于 2026 年 1 月 21 日发出召开第十一届董事会第六 次会议的通知，并于 2026 年 1 月 23 日以通讯方式召开本次会议，会议应参与表决 的董事 9 人,实际参与表决的董事 9 人，符合《公司法》和《公司章程》的规定。经 到会董事充分讨论，审议通过如下议案： ...

Core Insights - In 2025, Hubei province achieved a record high with 4 new Class I innovative drugs and 3 Class III innovative medical devices approved for market, with Wuhan contributing 3 of the Class I drugs [1][2] Group 1: Innovative Drug Developments - Hubei's new Class I innovative drugs include two significant products from local companies: He Yuan Bio (688765.SH) and Jianmin Pharmaceutical (600976.SH) [1][2] - He Yuan Bio's recombinant human albumin injection (rice-based) is the first approved recombinant human serum albumin product in China, addressing the issue of reliance on imported albumin [2][5] - Jianmin Pharmaceutical's pediatric heat-reducing patch is the only approved traditional Chinese medicine gel patch for children in the last 20 years, filling a market gap for pediatric external treatments [3] Group 2: Policy Support and Industry Ecosystem - Hubei's innovative achievements are supported by a robust industrial ecosystem, with over 3,000 biopharmaceutical companies in the Optics Valley Biotech City, creating a comprehensive industry chain from R&D to production [4] - The Hubei provincial government aims to double the biopharmaceutical industry's revenue to 250 billion yuan by 2027, with specific targets for companies exceeding 500 million yuan, 100 million yuan, and 50 million yuan in revenue [4] - The provincial drug regulatory authority has implemented measures to enhance the approval process for innovative products, significantly boosting the vitality of the pharmaceutical industry [4][5]

Group 1 - The National Medical Products Administration announced the approval of three Class I innovative drugs from Wuhan, marking the city's best historical performance in original drug innovation and research [1] - The approved drugs are classified as "global firsts" or "fill market gaps," highlighting their significance in the pharmaceutical industry [2] - The first drug, "Recombinant Human Albumin Injection (Rice)," developed by Wuhan Heyuan Biotechnology Co., utilizes genetic engineering to produce human-like albumin from rice, effectively turning rice into a "blood bank" [2] Group 2 - The second drug, "Children's Cow Bile Heat-Reducing Patch," developed by Jianmin Pharmaceutical Group, is the only approved traditional Chinese medicine gel patch for children in the last 20 years, filling a clinical gap in pediatric fever treatment [2] - The third drug, "Oral Hexavalent Recombined Rotavirus Live Attenuated Vaccine," developed by Wuhan Institute of Biological Products, is the world's first hexavalent rotavirus vaccine, capable of preventing six types of rotavirus-induced diarrhea, breaking the long-standing monopoly of foreign companies [2]

Market Overview - The Chinese medicine sector experienced a decline of 0.3% on December 31, with *ST Changyao leading the drop [1] - The Shanghai Composite Index closed at 3968.84, up 0.09%, while the Shenzhen Component Index closed at 13525.02, down 0.58% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - ST Ziling: closed at 4.35, up 2.84% with a trading volume of 476,800 shares and a turnover of 207 million yuan [1] - Guohan Pharmaceutical: closed at 11.21, up 2.66% with a trading volume of 48,400 shares and a turnover of 54.01 million yuan [1] - Major decliners included: - *ST Changyao: closed at 0.87, down 8.42% with a trading volume of 828,300 shares and a turnover of 73.23 million yuan [2] - ST Huluwa: closed at 7.62, down 4.63% with a trading volume of 176,200 shares and a turnover of 134 million yuan [2] Capital Flow - The Chinese medicine sector saw a net outflow of 399 million yuan from institutional investors, while retail investors contributed a net inflow of 376 million yuan [2] - The sector's capital flow details indicate: - Dong'e Ejiao had a net inflow of 27.6 million yuan from institutional investors, but a net outflow of 14.69 million yuan from speculative funds [3] - Guohan Pharmaceutical experienced a net inflow of 8.03 million yuan from institutional investors, but a net outflow of 9.69 million yuan from retail investors [3]

Market Overview - The Chinese medicine sector experienced a decline of 0.32% on December 30, with *ST Changyao leading the drop [1] - The Shanghai Composite Index closed at 3965.12, down 0.0%, while the Shenzhen Component Index closed at 13604.07, up 0.49% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Taiji Group (600129) with a closing price of 18.25, up 2.07% [1] - Wanbangde (002082) at 13.89, up 1.98% [1] - Fangsheng Pharmaceutical (603998) at 11.29, up 1.62% [1] - Conversely, *ST Changyao (300391) saw a significant drop of 19.49%, closing at 0.95 [2] Trading Volume and Value - The trading volume and value for key stocks were as follows: - Taiji Group: 87,200 shares traded, with a transaction value of 159 million [1] - Wanbangde: 164,400 shares traded, with a transaction value of 227 million [1] - Fangsheng Pharmaceutical: 48,000 shares traded, with a transaction value of 53.82 million [1] Capital Flow - The Chinese medicine sector experienced a net outflow of 231 million from institutional investors, while retail investors saw a net inflow of 280 million [2] - The capital flow for specific stocks included: - Wanbangde with a net inflow of 48.79 million from institutional investors [3] - Taiji Group with a net inflow of 18.53 million from institutional investors [3] - *ST Changyao had a net outflow of 19.49% [2]

Core Viewpoint - The company acknowledges that its stock price is influenced not only by its operational quality but also by various external factors such as economic environment, industry conditions, and consumer behavior [2] Group 1: Company Strategy and Focus - The company remains focused on its core business development to enhance its sustainable operational capacity, core competitiveness, and investment value [2] - The company is committed to actively returning value to its shareholders through various initiatives [2] Group 2: Investor Relations - The company maintains effective communication with the market through investor relations management activities [2] - Shareholder information will be disclosed in regular reports, including quarterly reports, encouraging stakeholders to stay informed [2]